Michael Gelband’s MaxCyte MXCT Stock Holding History

Michael Gelband’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,261	Closed	-$86K	–	2257
2022 Q1	$86K	Buy	+12,261	New	+$83.7K	﹤0.01%	2017

Other funds holding MXCT

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Michael Gelband's MXCT Position: Q2 2022 in Review

Michael Gelband sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 12,261 shares — an estimated $86K sold.

Michael Gelband first reported a position in MXCT in Q1 2022 and held it in 1 quarter. The position peaked at $86K in Q1 2022. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

Michael Gelband reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 12,261 MaxCyte shares in Q2 2022, an estimated $86K.
Michael Gelband first reported a position in MaxCyte in Q1 2022 and held it in 1 quarter.
Michael Gelband's MaxCyte position peaked at $86K in Q1 2022.
102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.